Huge news flow—senior advisor appointment, major conference presentations—but price action is still reeling from the Q1 hangover. 🛑 RSI in the low 40s is tepid, not panicked. The 9-period WMA is flirting with the 21-period; a golden cross is *this* close. Volume today is light, no conviction yet. This needs a catalyst to break out. **SELL** the pop if we get one, or **HOLD** if you've got diamond hands. Waiting for confirmation. 👀

Alright, listen up. The news here is pure rocket fuel: oversubscribed financing, FDA alignment, and data presentations. That's the story. 📈 Technically, the stock just cooled off from a 42% weekly surge. The RSI is backing down from overbought territory—healthy! The 9-period EMA is holding above the 21, so the short-term trend is still your friend. Big volume on down days suggests some profit-taking, but the institutional news flow is overwhelmingly positive. This dip looks like a gift. **Verdict: BUY the narrative, ride the trend.** #BiotechBounce

Big news week for Relmada with FDA paths and a fresh $100M raise. 💪 The stock's finally waking up, pushing past both key WMAs. RSI is warm but not screaming, and today's volume surge on an up-day feels like conviction, not just noise. This looks like the start of a real move on real catalysts. BUY the momentum. #BiotechBreakout

FDA just gave them TWO paths to approval for their bladder cancer drug? That's huge! 📈 The stock's been volatile but keeps bouncing off support around $4. The RSI is hot, but the real story is the news. This feels like a coiled spring. BUY before the crowd fully prices in this regulatory clarity. #BiotechBounce

Relmada’s stock is on a wild ride! 🎢 The recent surge (close: $0.69, up 82% in a day) screams bullish momentum, backed by massive volume (31M vs. avg). The 9-day EMA just crossed above the 21-day, a classic buy signal. But RSI at 90.7 is *deeply* overbought—profit-taking likely ahead. News mix (failed trials + new licensing) adds volatility. Short-term traders might ride the wave, but caution’s key—this could snap back hard. Hold if you’re risk-tolerant; sell if you prefer stability. 🚀⚠️